Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Immuron Ltd

  • Public · NASDAQ: IMRN
  • 7 employees
$10.2MMarket cap
7Employees
IMRNNASDAQ
2007IPO

About Immuron Ltd

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Market cap
$10.2M
NASDAQ: IMRN

15-minute delayed · data by Polygon.io

Market cap
$10.2M
Open
Day range
Prev close
Volume
IPO date
Dec 13, 2007

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review Immuron Ltd.

Write a review
Explore

Similar companies

Browse all →